NASDAQ:VIVO Meridian Bioscience (VIVO) Stock Price, News & Analysis → The #1 Crypto That You Don’t Own… Yet (From Crypto 101 Media) (Ad) Free VIVO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$33.97▼$33.9750-Day Range$33.00▼$33.9752-Week Range$20.35▼$34.38VolumeN/AAverage Volume973,737 shsMarket Capitalization$1.50 billionP/E Ratio35.02Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Meridian Bioscience alerts: Email Address Ad Paradigm PressDiscover How to Turn $10,000 into $1 MillionToday, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.That will slam shut June 25. About Meridian Bioscience Stock (NASDAQ:VIVO)Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.Read More Ad Paradigm PressDiscover How to Turn $10,000 into $1 MillionToday, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.That will slam shut June 25. VIVO Stock News HeadlinesMay 11, 2024 | finance.yahoo.comBiomerica, Inc. (BMRA)February 8, 2024 | health.usnews.comMeridian Meadows Transitional CareNovember 28, 2023 | benzinga.comMeridian Bioscience Earns EcoVadis Bronze Medal in Recognition of Its Dedication to SustainabilityJuly 25, 2023 | finance.yahoo.comMeridian Bioscience Continues Expansion of H. pylori Diagnostic Testing Solutions with FDA Clearance of Premier HpSA FlexMay 17, 2023 | marketwatch.comRapid Testing Kits Market Size Opportunities, Top Countries Data, Future Trends and Share Forecast 2028April 27, 2023 | marketwatch.comRapid Testing Kits Market Size with Growth Opportunities, Top Countries Data, Future Trends and Share with Revenue Forecast 2028April 19, 2023 | thestreet.comMeridian Bioscience Stock To Go Ex-dividend Tomorrow (VIVO)April 19, 2023 | markets.businessinsider.comMeridian Bioscience Announces FDA Clearance for Innovative Curian® Shiga Toxin AssayApril 6, 2023 | bizjournals.comFormer executives at Meridian Bioscience subsidiary facing federal chargesApril 5, 2023 | markets.businessinsider.comMeridian Bioscience Comments on DOJ Announcement Regarding Former Executives of Magellan DiagnosticsMarch 30, 2023 | thestreet.comMeridian Bioscience Stock Hits New 52-Week Low (VIVO)March 26, 2023 | thestreet.comMeridian Bioscience Stock Hits New 52-Week High (VIVO)March 23, 2023 | usnews.comPhoenix Union Bioscience High SchoolMarch 20, 2023 | marketwatch.comGlobal "Diagnostics PCR Market" 2023: On-going Trends and Growth Insights by 2027February 1, 2023 | finanznachrichten.deMeridian Bioscience, Inc.: SD Biosensor and SJL Partners Complete Transaction to Acquire Meridian BioscienceFebruary 1, 2023 | finance.yahoo.comMeridian Bioscience finalizes $1.53B sale to South Korean-based firmsJanuary 31, 2023 | finance.yahoo.comSD Biosensor and SJL Partners Complete Transaction to Acquire Meridian BioscienceDecember 29, 2022 | benzinga.comMeridian Bioscience's Return On Capital Employed OverviewDecember 13, 2022 | seekingalpha.comMeridian Biosciences: Why I Moved On But May Go Back InDecember 12, 2022 | finance.yahoo.comMeridian Bioscience Announces Anticipated Closing Date of the Pending MergerDecember 12, 2022 | finance.yahoo.comMeridian Bioscience sets closing date for $1.53 billion dealNovember 22, 2022 | seekingalpha.comMeridian Bioscience Non-GAAP EPS of $0.21, revenue of $65.67MNovember 22, 2022 | finance.yahoo.comMeridian Bioscience (VIVO) Q4 Earnings Surpass EstimatesNovember 17, 2022 | finance.yahoo.comBellRing Brands (BRBR) Beats Q4 Earnings EstimatesOctober 15, 2022 | uk.finance.yahoo.comMeridian Bioscience, Inc. (VIVO)See More Headlines Receive VIVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Meridian Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today6/15/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:VIVO CUSIP58958410 CIK794172 Webwww.meridianbioscience.com Phone(513) 271-3700Fax513-271-3762Employees702Year Founded1977Profitability EPS (Most Recent Fiscal Year)$0.97 Trailing P/E Ratio35.02 Forward P/E Ratio40.93 P/E GrowthN/ANet Income$42.46 million Net Margins12.70% Pretax Margin16.31% Return on Equity16.74% Return on Assets13.09% Debt Debt-to-Equity Ratio0.07 Current Ratio3.63 Quick Ratio2.46 Sales & Book Value Annual Sales$333.02 million Price / Sales4.49 Cash Flow$1.78 per share Price / Cash Flow19.13 Book Value$8.41 per share Price / Book4.04Miscellaneous Outstanding Shares44,010,000Free Float42,996,000Market Cap$1.50 billion OptionableOptionable Beta0.23 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesJohn Patrick KennyChief Executive Officer & Executive DirectorAndrew S. KitzmillerChief Financial Officer & Executive Vice PresidentJulie SmithChief Accounting Officer, Senior VP & ControllerEmerson C. MoserSenior Vice President & General CounselLourdes WeltzienExecutive Vice President-Life ScienceKey CompetitorsHeskaNASDAQ:HSKAOxford Immunotec GlobalNASDAQ:OXFDRiot PlatformsNASDAQ:RIOTDENTSPLY SIRONANASDAQ:XRAYMerit Medical SystemsNASDAQ:MMSIView All Competitors VIVO Stock Analysis - Frequently Asked Questions How were Meridian Bioscience's earnings last quarter? Meridian Bioscience, Inc. (NASDAQ:VIVO) posted its quarterly earnings data on Friday, November, 12th. The company reported $0.24 earnings per share for the quarter, topping analysts' consensus estimates of $0.21 by $0.03. The firm earned $76.20 million during the quarter, compared to analysts' expectations of $68.40 million. Meridian Bioscience had a net margin of 12.70% and a trailing twelve-month return on equity of 16.74%. During the same quarter last year, the company posted $0.19 EPS. What is Jack Kenny's approval rating as Meridian Bioscience's CEO? 7 employees have rated Meridian Bioscience Chief Executive Officer Jack Kenny on Glassdoor.com. Jack Kenny has an approval rating of 56% among the company's employees. This puts Jack Kenny in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Meridian Bioscience own? Based on aggregate information from My MarketBeat watchlists, some companies that other Meridian Bioscience investors own include AbbVie (ABBV), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Pfizer (PFE), AT&T (T), Gilead Sciences (GILD), Amgen (AMGN), Alibaba Group (BABA) and Tesla (TSLA). Does Meridian Bioscience have any subsidiaries? The following companies are subsidiares of Meridian Bioscience: Exalenz Bioscience.Read More This page (NASDAQ:VIVO) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredKiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does ...Porter & Company | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Meridian Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Meridian Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.